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Abstract 
A PLGA-based multifunctional biodegradable nanoparticle platform co-harboring 
hematoporporphyrin and indocyanine green has been developed.  In vitro studies demonstrate 
ultrasound and light stimulated generation of cytotoxic reactive oxygen species.  In vivo 
studies demonstrate that the ICG component facilitates nIR fluorescence imaging that 
demonstrates accumulation of IV- administered nanoparticles in tumours.  In vivo studies also 
demonstrate ultrasound- and light-mediated inhibition of tumor growth in animals treated 
with the platform.  Since the platform consists entirely of clinically-approved agents it could 
find use in sonodynamic- and photodynamic-based therapies for cancer.   
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1. Introduction  
The search for non-invasive or minimally invasive approaches for the treatment of more 
deeply-seated cancers has led to the development of therapeutic regimes such as 
photodynamic therapy (PDT) [1].  The approach is based on the administration of a sensitiser 
that is taken up by tumours and is subsequently stimulated by light to produce cytotoxic 
reactive oxygen species (ROS).   Although it delivers site-specific therapy, its acceptance in 
clinical practice as a mainstream cancer treatment modality is hindered, for the most part, by 
accumulation of sensitisers in skin [2] and the inability of light to penetrate deeply into living 
tissues [3] .  The former necessitates the protection of patients from exposure to direct light 
and the latter precludes the treatment of inaccessible or more deeply-seated tumours.  An 
alternative emerging approach involves the use of ultrasound to ‘activate’ the sensitising drug 
and this is more generally known as sonodynamic therapy (SDT) [4].   Although many of the 
sensitisers used in PDT can also serve as sonosensitisers, the mechanism by which the 
sensitiser is activated by ultrasound in SDT is less clear.  It is however generally accepted 
that site-specific toxicity results from the generation of ROS on exposure to ultrasound and a 
number of hypotheses have been suggested, all of which involve events that derive from 
ultrasound-induced cavitation [5,6]. This is supported by the observation that when 
sensitisers are chemically conjugated to the surface of microbubbles, the generation of ROS 
is enhanced in an acoustic field [7].  
Since SDT uses ultrasound to activate the sensitiser, the major perceived clinical 
benefit is that it may be used to target more deeply-seated lesions since ultrasound can 
penetrate tissues more easily than light.    Because SDT offers the potential to target more 
deeply seated lesions, accumulating sensitizer solely at the target site becomes essential in 
order to preclude uptake by non-target tissues and in particular by tissues that interspace the 
actual target and the ultrasound source.   Achieving this would also preclude overall patient 
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photosensitization; an adverse effect associated with many sensitisers employed in PDT as 
mentioned above. One potential means of accumulating sensitizer at the lesion would be to 
use a nanoparticle platform and exploit the enhanced permeation and retention (EPR) 
phenomenon exhibited by many solid tumors [8]   Masters et al. have reviewed nanoparticle-
based platforms for use in PDT and describe their ability to accumulate sensitizer in target 
lesions, although the inability of light to penetrate deeply into tissues in PDT remains a 
challenge [9].  Since tissue penetration is not a challenge for SDT, the use of a nanoparticle-
based platform for more site-specific sensitizer delivery would provide significant advantage.   
Recently You et al. described the use of TiO2 nanoparticles in SDT demonstrating 
preferential uptake by tumours and therapeutic efficacy [10].    In addition to aiding the 
preferential accumulation of sensitiser in target lesions, nanoparticles can also be exploited to 
deliver multiple functionalities and this approach has been used to incorporate diagnostic as 
well as therapeutic capabilities in a single formulation.  In another recent study, Chen et al. 
described the use mesoporous silica grown on reduced graphene nanosheet that was capped 
with rose bengal-conjugated to iron-oxide nanoparticles and demonstrated its use to 
simultaneously generate cytotoxic ROS and induce hyperthermia in an acoustic field [11].  
Here the authors suggested that the graphene sheet provided a heat conducting base that 
induced hyperthermia and the iron nanoparticles provided seeding of cavitation to enhance 
ultrasound-enhanced ROS generation by rose bengal.  The particles could also be used to 
magnetically target the construct to a specific locus and could provide a means of assessing 
accumulation at a target site using magnetic resonance imaging (MRI).  Although a variety of 
novel and indeed extremely elegant nanoparticle-based platforms incorporating sensitisers 
and exhibiting multiple functionalities have recently been suggested for SDT, their potential 
behavioral characteristics in patients and their clinical acceptability remain unproven.    
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Interestingly the first studies reporting the phenomenon of SDT exploited 
hematoporphyrin (HP) as the sensitizer [4].  Although its use as a sensitiser for SDT would 
be clinically acceptable, since it is a natural prophyrin and indeed derivatives of this are 
currently used clinically for PDT (Photofrin), its direct clinical exploitation is hindered by its 
limited solubility in aqueous media and its adverse biodistribution characteristics which result 
in prolonged skin photosensitization [12,13].   Since it has been suggested that 
nanotechnology could play a very significant role in the clinical exploitation of porphyrins 
[14], primarily because it could resolve issues associated with limited solubility and impact 
favorably on biodistribution, we decided to explore the possibility of using HP as a sensitiser 
payload in a nanoparticle-based platform.  Poly(DL-lactic-co-glycolic acid)  (PLGA) was 
used as a platform polymer because it is biocompatible, biodegradable and is approved by the 
United States Food and Drug Administration for use in humans [15].  In order to provide an 
imaging capability in the platform, it was decided to incorporate the cyanine dye, 
indocyanine green (ICG) into the HP-containing particles because it is a clinically-approved 
near infra-red (nIR) fluorescence imaging agent that is used to assess vascular patency [16].    
Although ICG has also been reported to serve as a sensitizer that responds both to light and 
ultrasound, it was used in this study at concentrations that were at least 30-fold lower than 
those required to elicit a therapeutic effect [17].   Here, we describe the physicochemical 
characterization of this stimulus-responsive platform.   Using in vitro and in vivo target 
systems, it is shown to exhibit cytotoxic activity in response to light, ultrasound and 
combinations of both.  The diagnostic capability of the platform and its exploitation therapy 
design is also described.  The potential benefits offered by such a system in the treatment of 
solid tumours is discussed. 
 
 
5 
 
2. Materials and Methods 
2.1 Preparation and characterization of nanoparticles 
50 mg of hematoporphyrin dichloride (HP) (>75%; Sigma Aldrich, UK) and 10 mg of 
indocyanine green (ICG) (Sigma Aldrich, UK) were dissolved in 3 mL of ethanol.  Where HP 
containing nanoparticles were produced in the absence of ICG, the latter was omitted from 
this solution. A 100 mg quantity of poly(DL-lactic-co-glycolic acid) (75:25; molecular 
weight: 66,000 – 107,000; Sigma Aldrich, UK) was dissolved in 4 mL of acetone.  Following 
dissolution, both solutions were mixed and added dropwise to 40 mL of a vigorously-stirred 1 
% (w/v) aqueous solution of polyvinyl alcohol (MW 30,000 – 70,000; 87 – 90% hydrolyzed; 
Sigma Aldrich, UK) over a 7 min period.  To enhance emulsification an ultrasound probe (6 
mm; 20 kHz,Vibra-Cell; Sonics and Materials, Newton, CT, USA) was immersed in the 
polyvinyl alcohol solution and operated at 91 Watts (70 %  of net power output) during 
addition of the PLGA mixture.   The suspension was then stirred for 3 h and nanoparticles 
were recovered and washed once in distilled water, then in phosphate buffered saline (PBS) 
and finally in distilled water by centrifugation at 15,000g for 30 min.   The pellet was then 
suspended in distilled water and centrifuged at 500g for 3 min to remove larger aggregates 
before finally lyophilizing and storage at -20
o
C.    To determine the HP and ICG content, 1 
mg of nanoparticles was dissolved in acetone and the concentration of HP and ICG was 
determined using UV/Vis absorption spectrophotometry at 500nm and 800nm, respectively.   
Encapsulation efficiency is expressed as the mass of each payload recovered in the 
nanoparticle preparation as a % the mass of each payload initially employed in the 
preparation.  UV/Vis absorbance scans of nanoparticle preparations were performed using 
dilutions of a 1 mg/mL suspension of each nanoparticle preparation in PBS.  In order to 
examine passive release of payload from the nanoparticles preparations, 1 mL of a 1 mg/mL 
suspension in PBS was placed inside dialysis tubing (SpectroPor, MW cut-off: 50,000, 
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Spectrum Laboratories, Breda, The Netherlands) and this was then placed in a beaker 
containing 25 mL of distilled water.  The solution outside the tubing was stirred using a 
magnetic stirrer and samples were harvested at the indicated times.  HP and ICG that diffused 
into the external solution were determined by measuring the absorbance at 500nm and 
800nm, respectively. 
2.2 Determination of nanoparticle size 
Dynamic light scattering was employed to determine the diameter of the nanoparticles by 
analyzing dilutions of a 1 mg/mL suspension of particles in PBS using a Malvern Zetasizer 
Nano Z system (Malvern Instruments, Worcestershire, UK) and Zetasizer software version 
6.12.    The diameter of the nanoparticles was also determined using scanning electron 
microscopy by initially drying a sample of particles onto aluminum stubs, sputter coating 
with gold/palladium for 3 min at 18 mA and subsequently visualizing under high vacuum 
mode using a Quanta Environmental scanning electron microscope (FEI, Hillsboro, OR, 
USA).   
2.3 Determination of ROS production 
Ultrasound- and light-mediated ROS generation was determined using oxidation of 1,3-
diphenylisobenzofuran (DPBF) as described previously [6].  Essentially a nanoparticle 
preparation (1 mg/mL) was added to a 10 µM solution of DPBF prepared in an ethanol:water 
(50:50) mixture, aerated for 10 min and exposed to ultrasound at the indicated power 
densities (expressed as spatial average, temporal peak) for 60 min.  A Sonidel SP100 
sonoporator (Sonidel Ltd., Dublin, Ireland) was used in these studies and the instrument 
emitted ultrasound at a frequency of 1 MHz.  During exposures, a 50% duty cycle (pulse 
repetition rate = 100 Hz) was employed.  For treatment with light a Fenix LOD white light 
emitting diode (700mW/cm
2
) (Fenix, Denver, USA) was used.   Samples were harvested and 
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scanned using UV/Vis spectrophotometry and ROS generation was determined by a 
reduction in absorbance at 410 nm relative to untreated control samples.  Because of the 
photosensitive nature of the NP preparation, exposure to light was minimized during the 
studies. 
2.4 Mammalian cell culture and treatment in vitro 
RIF-1 cells were maintained in RPMI 1640 medium supplemented with glutamine 
(GlutaMAX, Invitrogen, UK) and 10% (v/v) fetal bovine serum in a humidified atmosphere 
containing 5% CO2 at 37
o
C as described previously [17].  Cells were dispensed into the wells 
of a 96-well plate at a concentration of 2 x 10
4
 cells/well in serum-containing medium and 
incubated overnight prior to treatment.  The medium was subsequently replaced by serum 
free medium and 20 µL aliquots of a 1 mg/mL suspension of nanoparticles were dispensed 
into each well.  3 h later, medium was replaced with serum-containing medium and wells 
were treated with light, ultrasound or a combination of both.  For treatment with light a Fenix 
LOD white light emitting diode (700mW/cm
2
) (Fenix, Denver, USA) was placed directly 
under each well to be treated.  Cells were treated for 30 s and placed back in the incubator 
overnight.  Cell viability was subsequently determined using an MTT-based cell viability 
assay and viability was expressed as a % of an untreated control population as described 
previously [17].   For ultrasound treatments, the transducer of a Sonidel SP100 sonoporator 
(Sonidel Ltd., Dublin, Ireland) was placed in direct contact with the bottom of each well to be 
treated.  An ultrasound contact gel was employed to ensure contact with the bottom of each 
well and treatment consisted of exposing each well to ultrasound at a frequency of 1 MHz for 
30 s at a power density of 2.5 W/cm
2
 (spatial average, temporal peak: SATP) and using a 
50% duty cycle with a pulse repetition rate of 100 Hz.   Cells were again incubated overnight 
following treatment and cell viability was subsequently determined using the MTT-based cell 
viability assay. 
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2.5 Tumour treatment and nIR imaging  
Tumours were established by subdermal injection of 1 x 10
6
 RIF-1 cells in 100 µL of PBS 
into the rear dorsum of host animals (C3H/HeN mice) as described previously [17].  Animals 
were treated humanely and in accordance with licensed procedures under the UK Animals 
(Scientific Procedures) Act, 1986.   When tumours had reached an average size of 250 mm
3
, 
animals were randomly distributed into groups for treatment with nanoparticles alone, 
nanoparticles plus light, nanoparticles plus ultrasound, nanoparticles plus light followed by 
ultrasound.  In addition, controls without treatment and treated with light plus ultrasound in 
the absence of nanoparticles were employed. Animals were anaesthetized during all 
treatments using intraperitoneal administration of 1:2 dilutions of a 1:1 mixture of 
Hypnorm/Hypnovel. Where animals were treated with nanoparticles, 50 uL aliquots of 
nanoparticles at a dose of 6.7 mg nanoparticles/ mL of PBS were intravenously administered 
to each animal.  Animals were then rested for 6 h before receiving treatment.  For treatment 
with light, tumours were exposed to the Fenix LED emitting white light at a dose of 700 
mW/cm
2
 for 3 min.  For ultrasound treatments, contact between the transducer and the target 
tumour was maintained using an ultrasound contact gel and lesions were treated for 3.5 min. 
using ultrasound at a frequency of 1 MHz and a power density of 3.5 W/cm
2
 (SATP) using a 
50% duty cycle at a pulse frequency of 100 Hz.   In cases where animals were treated with 
light and then ultrasound, the ultrasound was applied 15 min after treatment with light.  
Tumour volume was determined at the indicated times using 4(πr3)/3, where r is the radius 
obtained from measuring the geometric mean diameter using digital callipers.  Data are 
expressed as a % of the starting tumour volume.  For nIR fluorescence imaging, animals were 
anaesthetized using intraperitoneal administration of Hypnorm/Hypnovel and 50 µL 
nanoparticles were administered intravenously at a dose of 6.7 mg/mL in PBS.   Following 
administration, animals were placed in the chamber of a Xenogen IVIS
®
 Lumina imaging 
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system on fluorescence mode using the ICG filter set (excitation: 705-780 nm; emission: 810-
885 nm).  Data were captured, analysed using the Living Image® software package version 
2.60 and presented as arbitrary fluorescence units using the fluorescence efficiency mode to 
eliminate illumination intensity effects.   For ex vivo imaging to examine the tissue 
distribution of nanoparticles, animals were sacrificed at 24 h and organs were surgically 
excised.  Organs were then placed in the imaging system and fluorescence data were captured 
as described above. 
2.6 Statistical analyses   
Unless otherwise stated n = 3 in experiments.   Statistical analysis of significance was 
performed using analysis of variance and comparison of data groups was performed using the 
Tukey MCT in GraphPad Prism version 4.   
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3.  Results 
3.1 Characterisation of nanoparticles 
After preparation of the nanoparticles co-harboring HP and ICG using the solvent dispersion 
approach, suspensions were analysed using dynamic light scattering and it was found that 
particles had an average diameter of 200 - 270 nm with polydispersity indices (PDI) ranging 
from 0.118 to 0.320.  Data from a typical DLS run are shown in Fig.1S.   These data were 
confirmed using scanning electron microscopy as shown in Fig.1A.     
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Fig.1 (A) Scanning electron micrograph of nanoparticles (scale bar = 2 µm).  The scale bar 
represents 2 µm.   (B) Spectrophotometric scans of nanoparticles containing HP and HP 
together with ICG. 
 
To confirm the presence of HP and ICG in the nanoparticle preparation, 
spectrophotometric scans of nanoparticles containing HP alone and HP together with ICG 
were obtained.  The scan from the nanoparticles containing HP and ICG exhibited the 
characteristic absorption profile of HP together with an absorption peak characteristic of ICG 
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in the 800 nm region of the spectrum (indicated by the arrow in Fig.1b).   Spectrophotometric 
analysis following nanoparticle solvent extraction indicated that 1mg of nanoparticles 
contained 0.7 mg of HP and 40 µg ICG.  The high proportion of HP in the vehicle probably 
results from the limited solubility of HP in aqueous media.  From a 38% yield, these data 
indicated a 70% encapsulation efficiency for HP and 24% encapsulation efficiency for ICG. 
 In order to examine passive release of both HP and ICG from the nanoparticles, the 
preparation was incubated in PBS and the amount of HP and ICG leaking from the particles 
was determined by spectrophotometric analysis.  Results indicate that whilst the majority of 
HP (>70%) was released from the particles within a 40h period, a much lower percentage of 
the ICG was detected in the medium over this period (Fig.2A).   Since it had been 
demonstrated in numerous studies that the photodynamic effect can be exploited to generate  
 
Fig.2 (A) Release of payloads HP and ICG from nanoparticles and (B) ROS production using 
DPBF as a trap during exposure of nanoparticles (NP) to white light (WL) and ultrasound 
power densities ranging from 2 – 4 Wcm-2.   Error bars in (A) represent + SD where n = 3 
and in panel (B) error bars are omitted in the interests of clarity with data points 
representing the averages where n = 3.      
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 ROS from HP, it was decided to determine whether or not the HP-containing nanoparticles 
would mediate the generation of ROS in an acoustic field.   To this end, nanoparticles were 
exposed to white light and an acoustic field at a variety of ultrasound power densities.  The 
generation of ROS was determined using DPBF as a ROS trap as described previously [6]   
The data (Fig.2B) demonstrate that in the presence of either white light or ultrasound, ROS 
were generated in a time-dependent and ultrasound dose-dependent manner.   
3.2 In vitro studies using the nanoparticle platform 
Although nanoparticles provide a potential advantage in targeting agents to tumour tissues 
using the EPR effect, they can also provide benefit in aiding the cellular uptake of therapeutic 
agents [8].  In PDT or SDT, intracellular accumulation would provide advantage because 
internal organelles such as mitochondria serve as targets for ROS generated by those 
approaches [17].   Since the platform co-harbors ICG it was decided to determine whether or 
not this could be exploited together with nIR fluorescence imaging to assess cellular uptake 
of the platform by target cells in vitro.  To this end a mouse radiation-induced fibrosarcoma 
cell line (RIF-1) was employed as the target.  This cell line is used routinely in our 
laboratories as an in vitro target because it can also be used from a translational perspective to 
develop tumours in syngeneic host mice to provide in vivo targets [17].   Following 
incubation of the nanoparticles (5 µl of a 1 mg/mL suspension of nanoparticles in PBS) with 
target cells in 96- well plates, medium was replaced at the indicated times and plates were 
then examined for particle retention by cells using nIR fluorescence imaging.  The results are 
shown in Fig. 3A with the inset providing a typical result obtained from fluorescence 
imaging.   They demonstrate that particles are taken up by the cell population and uptake 
reaches saturation within 3 – 4h.  
 As shown in Fig.2B, the nanoparticles are capable of generating ROS in an acoustic 
field.   In order to demonstrate that the nanoparticle platform could provide stimulus-
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responsive cytotoxicity, nanoparticles were incubated with the RIF-1 cells for 3h to facilitate 
cellular uptake.  Cell populations were then treated with white light, ultrasound and a 
combination of both.   The effects of each treatment on cell viability are shown in Fig. 3B and 
demonstrate that when the nanoparticles are combined with light, ultrasound or light followed 
by treatment with ultrasound, a significant decrease (p<0.01) in cell viability was observed.    
While no statistically-significant difference was observed between nanoparticle-treated cells 
in the presence of either light or ultrasound, a significant decrease in viability  
 
Fig.3 (A) nIR fluorescence imaging to detect uptake of nanoparticles by RIF-1 tumour cells.  
Fluorescence is expressed as counts detected from each well and the inset shows a typical 
result from fluorescence imaging with increasing incubation time from left to right. (B) The 
effects of light, ultrasound and light plus ultrasound on the RIF-1 cell viability in the 
presence and absence of NPs and bars represent + the standard error.  ** p < 0.01   
 
was noted when the viability of cells treated with either stimulus alone was compared with 
cells treated with the combined stimuli.   It was interesting to note that when cells were 
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treated with either nanoparticles alone or the combined stimuli in the absence of 
nanoparticles no significant effect on cell viability was detected and this will be discussed 
below. 
3.3 In vivo studies using the nanoparticle platform 
Having established that the ICG payload could be used as a nIR fluorescence imaging probe 
(Fig.3A), it was decided to determine if this aspect could be used to monitor the distribution 
or fate of nanoparticles in vivo.  To this end, a preparation of nanoparticles consisting of 0.23 
mg (with respect to HP) in a 50 µL injection volume (PBS) was administered intravenously 
to tumor-bearing mice.   Whole-body nIR fluorescence imaging was performed and a strong 
signal was immediately evident at the tumour (Fig.4A, left inset).  The imaging  
 
                          A                                                      B 
Fig.4 (A) nIR fluorescence imaging signal from tumour and peripheral tissues.  Left insert is 
an image captured immediately after injection of nanoparticles and the right insert is an 
image captured at 24 h. Regions of interest are represented by circles and data are presented 
as the ratio of the signal obtained from the tumour relative to that obtained from peripheral 
tissue. (B) nIR fluorescence imaging of surgically harvested tissues. 
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system also detected a fluorescent signal from peripheral tissues as noted from the hind leg 
shortly after injection (Fig.4A, left inset) and this was used as a surrogate for more 
widespread circulatory distribution of the nanoparticles.   Monitoring signals from both the 
tumour and peripheral tissues demonstrated a rapid increase in fluorescence in the tumour 
followed by a dramatic overall decline within the first 6h post administration (Fig.2S).     
Over this period however it was noted that the signal from the peripheral tissues decreased 
more rapidly and approximately 90% had been removed by 6h.  Even after 24 h, the signal 
from the tumour was still visible (Fig.4A, right inset) and when this was quantitatively 
expressed as a ratio to the signal obtained from the peripheral tissues, the data indicated a 6-
fold accumulation of nanoparticles in the tumour within 6h and this ratio remained constant 
up to 24 h.   In order to confirm that nanoparticless were being accumulated in the tumour 
and to ascertain their tissue distribution, it was decided to image tissues that were surgically 
harvested from animals that were sacrificed 24 h after administration of nanoparticles.  The 
data obtained are shown in Fig. 4B and they demonstrate that while the nanoparticle load in 
the tumour is significantly higher than in most tissues analyzed, significant fluorescence 
signals were found in both the liver and kidney.  Data in Fig. 2A suggest that at 24 h, 16% of 
the ICG leaks from the nanoparticles and it is possible that some of the signal obtained in the 
kidney may result from leakage, nanoparticle degradation or a combination of both and may 
not completely reflect the presence of intact nanoparticles.    Nevertheless, an extremely low 
signal was observed in the skin and this will be discussed further below. 
 In order to demonstrate therapeutic efficacy using multiple stimuli, nanoparticles were 
administered intravenously to tumour-bearing animals at the dose described above.  
Approximately 6 h after IV administration of the nanoparticles, tumours were treated with 
ultrasound, white light or a combination of both.  In these studies, longer exposure times to 
both stimuli were chosen because of anticipated tissue attenuation that would not have 
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existed in the in vitro studies.  The data obtained are shown in Fig. 5 and they clearly 
demonstrate that while administration of either the nanoparticles or the stimuli had no impact 
on tumour growth, treatment using the nanoparticles together with each stimulus alone or in 
combination, resulted in a dramatic reduction in tumour growth.  Indeed, even at day 9, 
tumours had failed to reach their initial pre-treatment size.  In addition, for animals treated 
with stimuli together with nanoparticles, no obvious damage to skin was observed confirming 
the observation above that the skin of these animals was not sensitised to the stimuli.  
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Fig.5 The effects of light, ultrasound (U/S) and light plus ultrasound on RIF-1 tumour growth 
in the presence and absence of intravenously-administered nanoparticles (NP).  For the 
untreated control, tumours treated with light and ultrasound alone and those treated with NP 
alone, n = 3 animals per group.  For all other groups n = 4.   ** p < 0.01 when groups 
treated with nanoparticles plus stimuli are compared with those treated with either 
nanoparticles alone or stimuli alone on the indicated days.   
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Although the in vitro studies (Fig.3B) demonstrated that combining the stimuli resulted in a 
significant reduction in cell viability when compared with the effects obtained with each 
stimulus alone, no statistically significant decrease in tumour growth was detected in vivo 
when lesions were treated with the combined stimuli.   
 
 
4.  Discussion 
As outlined above, SDT offers significant advantage in providing site-specific therapy for 
more deeply-seated cancers.  However, in exploiting a highly tissue permeable stimulus such 
as ultrasound, it would be preferable if the sensitizer exhibited a significant degree of tumour 
specificity in order to preclude off-target effects, particularly in tissues lying between the 
target and the external ultrasound source.   In order to explore the potential benefits afforded 
by a nanoparticle-based platform in delivering sensitizer for SDT, it was decided to design a 
platform that consisted entirely of clinically-acceptable components and to this end, 
nanoparticles consisting of clinically-approved PLGA containing the endogenous porphyrin, 
HP and the clinically-exploited nIR imaging agent ICG were prepared.   The procedure 
chosen provided spherical nanoparticles with an average diameter of 270 nm and they 
compared favorably with those obtained using a similar method to prepare PLGA-based 
nanoparticles containing zinc (II) phthalocyanine for use in PDT [18].   While the 
encapsulation efficiency for HP was high, that for ICG was relatively low although it was 
noted that Saxena et al. reported lower encapsulation efficiencies in preparing ICG-
containing PLGA nanoparticles when similar ratios of ICG to PLGA were employed [19].    
We are unaware of any study describing the preparation of HP-loaded PLGA nanoparticles, 
although a previous study has described encapsulation of HP in PLGA microbubbles 
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(approximate dia. 2 µm) and in that study the encapsulation efficiency was 64% [20] which 
approximates the 70% encapsulation efficiency reported here.   The high levels of association 
between HP and PLGA in both studies may result from the limited solubility of HP in 
aqueous media which limits is use in either PDT or SDT.    Despite this, it was noted that the 
HP did leak from the nanoparticles with over 70% released over a 40 h period and this was 
similar to the rate of release from the PLGA microbubbles described above [20].   This could 
provide advantage because once particles become trapped in tumour tissues, the passively 
released HP would be available to sensitise the surrounding tissues and this would 
complement cellular uptake of nanoparticles (Fig.3A).  This aspect will be discussed further 
below.   Conversely, the inability of the particles to release significant quantities of ICG 
could fortuitously be beneficial from an imaging perspective because the presence of a nIR 
fluorescent signal would reflect the presence of intact particles and not the free dye.  Indeed, 
the fluorescence imaging capability of the nanoparticles was exploited here to demonstrate 
uptake by cell populations in vitro and it was found that the uptake saturation kinetics were 
similar to those reported in the literature for PLGA nanoparticles of the same shape and size 
[21,22].  
 Having demonstrated that the nanoparticle preparation could generate ROS in the 
presence of an ultrasonic field at power densities well below those employed for 
hyperthermal tissue ablation [23], it was also demonstrated that the platform could deliver 
cytotoxic effects following exposure to ultrasound, light and light followed by ultrasound 
(Fig.3B).  We believe that much of the toxicity delivered from the nanoparticles following 
exposure to stimuli results from stimulus-dependent generation of ROS from the HP 
component since the ICG was present in the particles at concentrations that were 30-fold 
lower than those required to elicit a cytotoxic effect [17].  In these studies, it was also found 
that the stimuli or nanoparticles had no effect on cell viability when used alone and this is a 
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very significant finding from a therapeutic perspective.  In exploiting the EPR effect with 
nanoparticles to target solid tumors it is now generally accepted that some form of molecular 
targeting capability must be incorporated into the platform in order to minimize off-target 
effects [24].  This is certainly the case when the payload is a cytotoxic agent because PLGA 
nanoparticles tend to accumulate in the liver and this could have negative consequences for 
the patient [25].   In the current study, the payload and stimuli are non-toxic and only elicit 
toxicity when both are combined.  This highlights one of the major benefits of the platform 
since it precludes the necessity for sophisticated molecular targeting strategies.    
 In exploring the behavior of the platform in mice bearing syngeneic tumours a dose of 
0.23 mg (with respect to HP) in a 50 µL injection volume was administered intravenously to 
tumor-bearing mice.   Based on an animal weight of 30 g/mouse, this dose represented 
approximately 4 times the dose of Photofrin® recommended by the United States FDA for 
PDT-based treatment of esophageal cancer, endobronchial cancer and high-grade dysplasia in 
Barrett’s Esophagus (2 mg/kg) [26].  The benefit afforded by inclusion of the HP in the 
nanoparticle platform is evidenced by the observation that it would not have been possible to 
inject this amount of HP intravenously in PBS because of its limited solubility in aqueous 
media.   Using whole body fluorescence imaging following administration of the platform it 
was possible to detect a strong fluorescence signal from tumours and peripheral tissues.   
Over time, the signals reduced in intensity although that in the tumours reduced more slowly 
(Fig.2S and Fig.4).   Although semi-quantitative, this level of analysis demonstrated that the 
imaging capability provided by the ICG in the nanoparticles permitted direct, real-time 
visualisation of the appearance and retention of those nanoparticles in tumour tissues as well 
as monitoring the disappearance of material from peripheral or non-target tissues.   The 
ability to observe these distributions in real time in the clinic would provide the practical 
benefit of being able to directly identify the appropriate time to administer the stimulus and 
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this would preclude damage to off-target tissues.    Subsequent fluorescence imaging analysis 
of tissues harvested at 24 h indicated significant signals from the tumour, liver and kidney 
with extremely low levels of fluorescence in all other tissues examine.    Although signals in 
the liver and kidney were high, this is a significant improvement on the distribution of 
hematoporphyrin derivative (a chemically-derivatised form of hematoporphyrin) following 
administration in its free form where 4-fold that found in the tumour was detected in the liver 
at 24 h post injection into mice [27]  The latter study also demonstrated accumulation of 
porphrin in the kidney that was 2.5-fold that in the tumour and levels in the skin were similar 
to that found in the tumour.   In our studies imaging of skin samples yielded a very low 
signal, indicating poor retention of nanoparticles in the skin and this would imply that the 
skin was not sensitised.  This could represent an additional benefit of the nanoparticle 
platform described here since one well-known side effect associated with porphyrin-based 
PDT is hypersensitivity of the skin to ambient light.  Despite the relatively qualitative nature 
of our analysis, the pattern of nanoparticle tissue distribution obtained from direct nIR 
fluorescence imaging exhibits striking similarities to those described in previous studies 
where more quantitative methods were employed to detect the distribution of PLGA 
nanoparticles in tissues [28].   Using PLGA nanoparticles harboring cisplatin, Alan et al. had 
shown significant accumulation of nanoparticle payload (cisplatin) in liver, kidney and spleen 
[25].   Using 
99m
Tc-labelled PLGA nanoparticles of similar size to those used in the current 
study and imaging with a gamma camera, Souza et al., demonstrated significant 
accumulation of nanoparticles in liver, kidney and spleen 8 h after administration [29].  As 
mentioned above, since the approach described in the current study employs payloads that are 
non-toxic in the absence of stimulus, the impact of accumulation in organs such as the liver 
and kidney would be of less clinical significance than a similar degree of accumulation of 
nanoparticles harboring a toxic chemotherapeutic drug.    
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 When tumours in animals treated with nanoparticles were exposed to light or 
ultrasound, similar reductions in tumour size were observed and this was in agreement with 
the data obtained during the in vitro studies.   These data confirm the observations from the in 
vitro studies and demonstrate that the SDT approach is as good as the clinically-accepted 
PDT-based approach using this nanoparticulate platform.   It was also noted in these studies 
that where nanoparticles and stimuli were used, no effects were observed on the skin 
overlying the tumours and this corroborated the imaging results which suggested that the skin 
did not contain any nanoparticles.   In addition, neither the nanoparticles nor the stimuli, 
when used separately, had any significant effect on tumour growth and this again emphasizes 
the benefit afforded by this stimulus-responsive platform.   Interestingly, no significant 
enhanced effect on tumour size was observed when both stimuli were combined as observed 
during the in vitro studies.   Indeed, a number of studies have demonstrated that combining 
ultrasound and light, results in better effects in vitro and in vivo using other sensitisers 
[4,6,30].   However, since translation of observations from in vitro to in vivo is somewhat 
challenging, particularly with ultrasound because of the difficulty associated with mimicking 
true in vivo exposure conditions, observing benefit afforded by the combined stimuli will 
necessitate further optimisation.  This could potentially involve a more detailed examination 
of the stimulus levels applied in vivo.    Nevertheless, despite the lack of an observed benefit 
afforded using the combined stimuli, the system could offer potential benefit in situations 
where PDT may be of limited use in the treatment of less accessible lesions.   As mentioned, 
one of the major benefits afforded by SDT is the ability of the stimulus to penetrate deeply 
into tissues.  In a recent study comparing SDT with PDT for the treatment of skin cancer 
(both melanoma and non-melanoma skin cancers) we have demonstrated that senstisers may 
be activated at depth using ultrasound as the stimulus [31].  In addition, it was found that 
ultrasound could also elicit a therapeutic effect in melanotic lesions where the presence of 
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melanin compromised the efficacy of PDT.   Since the current nanoparticulate platform can 
respond to both light and ultrasound, it could be activated with ultrasound to yield a 
therapeutic response when the use of light would be contraindicated.     
 In comparing the existing platform with other nanoparticle-based sensitisers for use in 
SDT, a recent review on the use of nanoparticles in SDT suggested that one of the limitations 
of singlet oxygen-generating nanoparticles is the short lifetime of that species (< 3.5 µs) 
which limits its diffusion distance thereby limiting therapeutic efficacy [32].  This would 
present a particular challenge where the actual nanoparticle itself is the sensitizer or where 
the sensitizer is covalently attached to the nanoparticle where stimulus-generated ROS would 
be expected to diffuse away from the actual sensitizer in order to elicit a cytotoxic effect 
[10,11, 32,33].  Such a limitation would also be exacerbated in less vascularized tumours and 
those comprising a high proportion of stroma, both of which are negative prognostic markers 
in cancer as a result of limited diffusion and dispersion of therapeutics throughout the tumour 
tissues.    Clearly, this is not the case with the nanoparticles described here and therapeutic 
efficacy may result, at least in part, from the ability of the HP to diffuse from the particles 
(Fig. 3A) and more effectively sensitise cells at the target site. In addition, because the 
nanoparticles are composed of a biodegradable polymer, degradation of the nanoparticles in 
the tumour would enhance release and dispersion of HP so that it could be taken up more 
effectively by tumour cells, thereby further negating limitations associated with the short 
lifetimes of stimulus-generated ROS.    
 Although others have reported the use of nanoparticle-based platforms in PDT and 
more recently in SDT [10, 11,32,33] none have described a single multifunctional, 
biodegradable nanoparticle-based preparation with diagnostic capabilities, composed of 
clinically-approved reagents for use in both SDT and PDT and enabling the slow release of 
sensitizer that could enhance dispersion of that sensitizer at the target site.  Use of the PLGA 
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nanoparticle platform enables the use of therapeutic doses of an otherwise insoluble 
porphyrin and provides a degree of tumour specificity that is superior to that obtained with 
clinically approved, porphyrin-based sensitisers.   The particles are non-toxic in the absence 
of stimulus and when used together with harmless doses of light and/or ultrasound, provide 
site-directed toxicity.   By using the imaging capability provided by ICG in the nanoparticles 
to monitor their uptake by target tissues and removal of nanoparticles from non-target tissues, 
we suggest that this aspect may be exploited to identify the appropriate time for stimulus 
administration in order to eradicate off-target effects.  It is also worth noting that the platform 
is flexible enough to accommodate alternative imaging agents that could further enhance the 
imaging capabilities of the system.  We suggest that this highly biocompatible and versatile 
nanoparticle-based platform provides a flexible, multifunctional formulation for use in 
photodynamic- and/or sonodynamic-based therapeutic regimes aimed at treating solid 
tumours. 
 
Acknowledgements 
This work was funded in part by a EUROSTARS award (Project No.E5650-UGen).  CMcE 
acknowledges the Department of Employment and Learning (DEL), Northern Ireland for a 
PhD studentship.  
References 
1. T.J Dougherty, G.B.Grindley, R. Fiel, K.R.Weishaupt and D.Boyle, Photodynamic 
therapy II.  Cure of animal tumors with hematoporphyrin and light.  J. Natl. Cancer 
Inst. 55 (1975) 115-121. 
2. T.J.Dougherty, C.J. Gomer, B.W.Henderson, G.Jori,,D. Kessel, M.Korbelik, J.Moan 
and Q. Peng, Photodynamic Therapy, J. Natl. Cancer Inst., 90 (1998) 889-905. 
24 
 
3. J.R. Starkey, A.K. Rebane, M.A. Drobizhev, F. Meng, A.Gong, A. Elliott, K. 
McInnerney and C.W. Spangler, New two-photon activated photodynamic therapy 
sensitizers unduce xenograft tumor regressions after near-IR laser treatment through 
the body of the host mouse, Clin Cancer Res., 14 (2008) 6564-6573. 
4. N. Yumita, R. Nishigaki, K. Umemura and S. Umemura, Hematoporphyrin as a 
sensitizer of cell-damaging effect of ultrasound. Jpn. J. Cancer Res., 80 (1989) 219-
222. 
5. D. Costley, C. McEwan, C. Fowley, A.P. McHale, J. Atchison, N. Nomikou and J.F. 
Callan, Treating cancer with sonodynamic therapy: a review, Int. J. Hyperthermia., 31 
(2015) 107-117. 
6. B. McCaughan, C. Rouanet, C. Fowley, N. Nomikou, A.P. McHale, P.A. McCarron 
and J.F. Callan, Enhanced ROS production and cell death through combined photo- 
and sono-activation of conventional photosensitizing drugs, Bioorg. Med. Chem. 
Lett., 21 (2011) 5750-5752. 
7. N. Nomikou, C. Fowley, N.M. Byrne, B. McCaughan, A.P. McHale and J.F. Callan., 
Microbuble-sonosensitiser conjugates as therapeutics in sonodynamic therapy,  Chem 
Commun (Camb)., 48 (2012) 8332-8334. 
8. V. Torchilin, Tumor delivery of macromolecular drugs based on the EPR effect, Adv. 
Drug Deliv. Rev., 63 (2011) 131-135. 
9. A. Master, M. Livingston and A. Sen Gupta, Photodynamic nanomedicine in the 
treatment of solid tumors: perspectives and challenges, J. Control. Release, 168, 
(2013) 88. 
10. D.G. You, V.G. Deepagan, W. Um, S. Jeon, S. Son, H. Chang, H.I. Yoon, Y.W. Cho, 
M. Swierczewska, S. Lee, M.G. Pomper, I.C. Kwon, K. Kim and H.J.Park., ROS-
25 
 
generating TiO2 nanoparticles for non-invasive sonodynamic therapy of cancer, Sci. 
Rep., 6 (2016) DOI: 10.1038/srep23200. 
11. Y.W. Chen, T.Y. Liu, P.H. Chang, P.H. Hsu, H.L. Liu, H.C. Lin and S.Y. Chen., A 
theranostic nrGO@MSN-ION nanocarrier developed to enhance the combination 
effect of sonodynamic therapy and ultrasound hyperthermia for treating tumor, 8 
(2016) 12648-12657.   
12. D. Mew, V. Lum, C-K Wat, G.H.N. Towers, C-H.C. Sun, R.J. Walter, W. Wright, 
M.W. Berns and J.G.Levy, Ability of specific monoclonal antibodies and 
conventional antisera conjugated to hematoporphyrin to label and kill selected cell 
lines subsequent to light activation.  Cancer Res., 45 (1985) 4380-4386. 
13. J. Moan and Q. Peng, An outline of the history of PDT in: T. Patrice (Ed), 
Photodynamic Therapy, Royal Society of Chemistry, Cambridge UK, (2003) 1-18. 
14. Y. Zhou, X. Liang, Z. Dia. Porphyrin-loaded nanoparticles for cancer theranostics, 
Nanoscale, 8 (2016) 12394-12405. 
15. M.S. Shive and J.M. Anderson, Biodegradation and biocompatibility of PLA and 
PLGA microspheres, Adv. Drug Deliv. Rev., 28 (1997) 5-24. 
16. X. Zheng, D. Xing, F. Zhou, B. Wu and W.R. Chen, Indocyanine green-containing 
nanostructure as a near infrared dual-functional targeting probes for optical imaging 
and photothermal therapy, Mol Pharm., 8 (2011) 447-456. 
17. N. Nomikou, C. Sterrett, C. Arthur, B. McCaughan, J.K. Callan and A.P. McHale, 
The effects of ultrasound and light on indocyanine-gree-treated tumour cells and 
tissues, ChemMedChem, 7 (2012) 1465-1471. 
18. E. Ricci-Junior and J.M. Marchetti, Preparation, characterization, photocytotoxicity 
assay of PLGA nanoparticles containing zinc (II) phthalocyanine for photodynamic 
therapy use, J. Microencapsul., 23 (2006) 523-538. 
26 
 
19. V, Saxena and M. Sadoqi, J. Shao, Indocyanine green-loaded biodegradable 
nanoparticles: preparation, physicochemical characterization and in vitro release.  Int. 
J. Pharm.,   278 (2004) 293-301. 
20. Y. Zheng, Y. Zhang, M. Ao, P. Zhang, H. Zhang, P. Li, L. Qing, Z. Wang and H. 
Ran, Hematoporphyrin encapsulated PLGA microbubbe for contrast enhanced 
ultrasound imaging and sonodynamic therapy.  J. Microencapsul., 29 (2012) 437-444.  
21. L. Chronopoulou, A. Amalfitano, C. Palocci, G. Nocca, C. Calla and A. Arcovito, 
Dexamethasone-loaded biopolymeric nanoparticles promote gingival fibroblasts 
differentiation. Biotechnol Prog., 31 (2015) 1381-1387. 
22. K.Y. Win and S.S. Feng, Biomaterials, Effects of particle size and surface coating on 
cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs, 26 
(2005) 2713-2722.  
23. Y, Zhou, L. Zhai, R. Simmons and P. Zhong, Measurement of high intensity focused 
ultrasound fields by a fiber optic probe hydrophone. J. Acoust. Soc. Am. 120 (2006) 
676-685. 
24. M. Nui, Y.W. Naguib, A.M. Aldayel, Y.C. Shi, S.D. Hursting, M.A. Hersh and Z. 
Cui.  Biodistribution and in vivo activities of tumor-associated macrophage-targeting 
nanoparticles incorporated with doxorubicin. Mol. Pharm. 11 (2014) 4425-4436 
25. N. Alam, V. Khare, R. Dubey, A. Saneja, M. Kushwaha, G. Singh, N. Sharma, B. 
Chandan and P.N. Gupta, Biodegradable polymeric system for cisplatin delivery: 
development, in vitro characterization and investigation of toxicity profile, Mater. Sci. 
Eng. C. Mater. Biol. Appl., 38 (2014) 85-93. 
26. Photofrin Prescribing information FDA (United States of America), 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020451s020lbl.pdf   
accessed June, 2016. 
27 
 
27. C.J. Gomer and T.J. Dougherty. Determination of [3H] and [14C] hematoporphyrin 
derivative distribution in malignant and normal tissue.  Cancer Res., 39 (1979) 146-
151. 
28. B. Semete, L. Booysen, Y. Lemmer, L. Kalombo, L. Katata, J. Vershcoor and H.S. 
Swai, In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as 
drug delivery systems, Nanomedicine, 6 (2010) 662-671 
29. A.C. Souza, A.L. Nascimento, N.M. de Vasconcelos, M.S. Jeronimo, I.M. Siqueira, 
L. R-Santos, D.O. Cintra, L.L. Fuscaldi, O.R. Pires Junior, R. Titze-de-Almeida, M.F. 
Borin, S.N. Bao, O.P. Martins, V. N. Cardoso, S.O. Fernandes, M.R. Mortari, A. C. 
Tedesco, A.C. Amaral, M.S.  Felipe and A.L. Bocca, Activity and in vivo tracking of 
amphotericin B loaded PLGA nanoparticles, Eur. J. Med. Chem. 95 (2015) 267-176. 
30. P. Wang, C. Li, X. Wang, W. Xiong, X. Feng, Q. Liu, A.W. Leung and C. Xu, Anti-
metastatic and pro-apoptotic effects elicited by combination photodynamic therapy 
with sonodynamic therapy on breast cancer both in vitro and in vivo, Ultrason. 
Sonochem. 23 (2015) 116-127. 
31. C. McEwan, H. Nesbitt, D. Nicholas, O.N. Kavanagh, K. McKenna, P. Loan, I.G. 
Jack, A.P. McHale, J.F. Callan, Comparing the efficacy of photodynamic and 
sonodynamic therapy in non-melanoma and melanoma skin cancer.   Bioorg. Med. 
Chem. 24 (2016) 3023-3028 
32. H. Xu, X. Zhang, R. Han, P. Yang, H. Ma, Y. Song, Z. Lu, W. Yin, X. Wu and H. 
Wang, Nanoparticles in sonodynamic therapy: state of the art review,  RCS Advances, 
6 (2016) 50697-50705. 
33. A. Sazgarnia, A. Shanei, N.T. Meibodi, H. Eshghi, H. Nassirli,  Sonodynamic 
therapy.  In vivo study on a colon tumor model.  J. Ultrasound Med., 30 (2011) 1321-
1329.  
28 
 
 
